Song Yanqi, Gu Yeqing, Guo Honglei, Yang Honghao, Wang Xuena, Wu Hongmei, Wang Aidi, Wang Mengxiao, Wang Haijin, Zhang Qing, Liu Li, Meng Ge, Liu Baoshan, Niu Kaijun
Department of Traditional Chinese Medicine, Tianjin Medical University General Hospital, Tianjin, People's Republic of China.
Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, People's Republic of China.
J Inflamm Res. 2023 Aug 5;16:3259-3269. doi: 10.2147/JIR.S416404. eCollection 2023.
This study aimed to prospectively investigate the association between mean platelet volume (MPV) levels and risk of benign prostatic hyperplasia (BPH) in a general Chinese adult male population, and assessed this association in metabolic syndrome (MetS) patients.
This study included a total of 14,923 male participants free from BPH at baseline. MPV was measured by the method of laser-based flow cytometric impedance according to the complete blood sample. BPH was defined as total prostate volume (TPV) ≥ 30 mL, TPV was determined by transabdominal ultrasonography. Multivariable Cox proportional hazards models were fitted to calculate hazards ratios (HRs) and corresponding 95% confidence intervals (CIs) for BPH risk with NLR levels.
During a median follow-up of 2.7 years, 4848 BPH cases were documented in total male participants, and 1787 BPH cases were documented in MetS participants. After adjusting for age, body mass index, smoking, alcohol and personal and family history of disease, the multivariable-adjusted HRs of BPH were 1.00 (reference), 1.03 (95% CIs 0.96, 1.11), 1.00 (95% CIs 0.92, 1.08) and 0.98 (95% CIs 0.90, 1.06), respectively, for participants with MPV in the 1st, 2nd, 3rd and 4th quartiles ( for trend = 0.47). In MetS patients, the multivariable-adjusted HRs of BPH were 1.00 (reference), 1.03 (95% CIs 0.90, 1.16), 0.99 (95% CIs 0.87, 1.14) and 1.01 (95% CIs 0.89, 1.15) ( for trend= 0.98), respectively.
A non-significant association was observed between MPV levels and risk of BPH, and no association in this association in MetS patients. Our findings support the notion that MPV levels may not be a target for BPH prevention and intervention.
本研究旨在前瞻性调查中国普通成年男性人群中平均血小板体积（MPV）水平与良性前列腺增生（BPH）风险之间的关联，并在代谢综合征（MetS）患者中评估这种关联。
本研究共纳入14923名基线时无BPH的男性参与者。根据全血样本，采用基于激光的流式细胞术阻抗法测量MPV。BPH定义为总前列腺体积（TPV）≥30 mL，TPV通过经腹超声测定。采用多变量Cox比例风险模型计算BPH风险与NLR水平的风险比（HRs）及相应的95%置信区间（CIs）。
在中位随访2.7年期间，男性参与者中共记录到4848例BPH病例，MetS参与者中有1787例BPH病例。在调整年龄、体重指数、吸烟、饮酒以及个人和家族疾病史后，MPV处于第1、2、3和4四分位数的参与者发生BPH的多变量调整后HR分别为1.00（参考值）、1.03（95%CI：0.96，1.11）、1.00（95%CI：0.92，1.08）和0.98（95%CI：0.90，1.06）（趋势P=0.47）。在MetS患者中，发生BPH的多变量调整后HR分别为1.00（参考值）、1.03（95%CI：0.90，1.16）、0.99（95%CI：0.87，1.14）和1.01（95%CI：0.89，1.15）（趋势P=0.98）。
观察到MPV水平与BPH风险之间无显著关联，在MetS患者中该关联也不存在。我们的研究结果支持MPV水平可能不是BPH预防和干预靶点的观点。
